Sun, Ming-Li http://orcid.org/0000-0002-0535-2545
Liu, Hui-Juan
Luo, Xiang-Dong
Wang, Yu
Zhang, Wei
Liu, Chen
Wang, Xinghe
Article History
Accepted: 13 December 2021
First Online: 21 January 2022
Declarations
:
: This trial was funded by Guangdong Sinocorp Pharmaceutical Co., Ltd, China.
: Xiang-Dong Luo, the third author, was a senior engineer at Guangdong Sinocorp Pharmaceutical Co., Ltd, China. Ming-Li Sun, Hui-Juan Liu, Xiang-Dong Luo, Yu Wang, Wei Zhang, Chen Liu and Xinghe Wang have no financial or other substantive conflicts of interest that may be construed to influence the results or interpretations reported in this manuscript.
: The protocol and all documents were reviewed and approved by the Institutional Review Board of Beijing Shijitan Hospital on 16 October 2017 (registration number: 2017Y123).
: All subjects signed the consent form under fully informed conditions prior to commencement of the trial.
: All researchers, participants, institutions, and sponsors consented to the submission of this report to the journal.
: All data generated or analyzed during this study are included in this published article.
: Ming-Li Sun, working as the sub-I of the trial, and first author of this article, wrote the first and successive versions of this manuscript. Hui-Juan Liu and Wei Zhang were principal research nurses for the clinical trial. Yu Wang was quality control (QC). Xinghe Wang was the principal investigator (PI) of the clinical trial and corresponding author of this article. Xiang-Dong Luo was the sponsor. All authors took part in the research design and contributed many constructive opinions and suggestions to the clinical trial and this study article. All authors approved the final version of the manuscript.
: Not applicable.